|
CBER Five-Year Research Plan Aims To Speed Adverse Event Analysis
CBER plans to rely heavily on the FDA’s new “Mini-Sentinel” surveillance pilot program to improve its ability to identify low-frequency adverse events involving licensed products.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives